Research Article

Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial

Table 2

Comparison between groups at 3, 12, and 24 months.

ParametersABMDC-group IConservative therapy-group II value (95% CI)

VAS at 3 months3.09 ± 0.646.75 ± 0.840.0001 (3.2659 to 4.0541)
MKSSSF at 3 months57.48 ± 8.1838.87 ± 6.330.0001 (−22.5247 to −14.6953)
Pain without movement at 3 months3.37 ± 0.494.34 ± 0.60.0001 (0.6804 to 1.2596)
Pain on movement at 3 months3.65 ± 0.607.09 ± 0.730.0001 (3.0867 to 3.7933)
Daily living at 3 months5.28 ± 1.024.59 ± 0.750.0056 (−1.1698 to −0.2102)
QOL at 3 months7.9 ± 0.644.81 ± 0.890.0001 (−3.4985 to −2.6815)
VAS at 12 months2.59 ± 0.066.71 ± 0.720.0001 (3.8558 to 4.3842)
MKSSSF at 12 months72.68 ± 13.1542.31 ± 5.720.0001 (−35.860 to −24.880)
Pain without movement at 12 months2.43 ± 0.504.5 ± 0.80.0001 (1.7196 to 2.4204)
Pain on movement at 12 months2.47 ± 0.557.06 ± 0.710.0001 (4.2547 to 4.9253)
Daily living at 12 months5.625 ± 1.214.75 ± 0.760.0021 (−1.4185 to −0.3315)
QOL at 12 months8.175 ± 0.594.81 ± 0.890.0001 (−3.7621 to −2.9679)
VAS at 24 months1.87 ± 0.426.34 ± 0.700.0001 (4.1671 to 4.7729)
MKSSSF at 24 months82.18 ± 3.7940.15 ± 5.880.0001 (−44.630 to −39.430)
Pain without movement at 24 months1.75 ± 0.434.81 ± 0.640.0001 (2.7732 to 3.3468)
Pain on movement at 24 months1.91 ± 0.396.9 ± 0.580.0001 (4.7300 to 5.2500)
Daily living at 24 months7.4 ± 0.795.03 ± 0.820.0001 (−2.7976 to −1.9424)
QOL at 24 months8.5 ± 0.504.34 ± 0.860.0001 (−4.5289 to −3.7911)